Table 2.

Descriptive analysis of neoadjuvant group

	Neoadjuvant group
	(n = 11)
Results	%	(n)
Reason for initiation
Unresectable	55%	(6/11)
High morbidity surgery	36%	(4/11)
Does of imatinib
400 mg	73%	(8/11)
300 mg	27%	(3/11)
Duration (Median months)	8.8	(4.5 to 33.9)
Response to imatinib
Complete response	9%	(1/11)
Partial response	82%	(9/11)
No response	9%	(1/11)
Progressive disease	0%	(0/11)
Post-neoadjuvant size (Median cm)	3.6	(2.6 to 11.0)
Size reduction (Median cm, %)	2.7, 39%	(0–6.1, 0–61%)